The outcomes of the present study demonstrated that the overall expression of MRGs is downregulated in patients with AD, and six genes—i.e., FUNDC1, MAP1LC3A, CSNK2A1, VDAC1, CSNK2B, and ATG5—were identified that can be used to construct an AD prediction model with high predictive ability across different datasets. This evidence concerns the gene FUNDC1 and Alzheimer disease.